+44 (0)203 011 5574 info@orthocg.com
Misonix Names Sharon Klugewicz Chief Operating Officer

Misonix Names Sharon Klugewicz Chief Operating Officer

Proven C-Suite Executive Brings Extensive Healthcare Industry Experience to New Role

FARMINGDALE, N.Y., March 04, 2019 (GLOBE NEWSWIRE) — Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that Sharon Klugewicz has been appointed Chief Operating Officer.

In this newly created position, Ms. Klugewicz will oversee all aspects of manufacturing, regulatory affairs, quality assurance and research & development. Her appointment reflects Misonix’s focus on driving operational excellence across the business to support accelerating demand for its leading ultrasonic products, while advancing the Company’s goals for continued growth and the enhancement of shareholder value. Ms. Klugewicz will report to Stavros Vizirgianakis, President and CEO of Misonix.

Stavros Vizirgianakis, President and Chief Executive Officer of Misonix stated, “In the first half of fiscal 2019, we undertook a range of initiatives focused on reducing inefficiencies across the business to best position Misonix for the future. We created the Chief Operating Officer position to accelerate the execution of our growth strategy following the successful alignment of our operating infrastructure earlier this year, and are extremely fortunate to have retained an industry executive with Sharon’s extensive record of accomplishments. Sharon brings a wealth of experience that will enhance our ability to execute on our growth strategy as we bring new solutions to market, expand into new geographies, address an increasing number of medical procedures and further leverage our in-house sales team and R&D capabilities. We are confident that Sharon’s operational expertise and business acumen will help ensure that we achieve our goals for sustainable revenue growth and profitability, and that our efforts yield the best possible outcomes for our shareholders.”

Most recently, Ms. Klugewicz served as Chief Quality & Regulatory Affairs Officer at Chembio Diagnostics Systems, as well as President of the Americas, and Chief Operating Officer. During her tenure, Ms. Klugewicz played a critical role in the company’s operational and commercial success, including manufacturing expansion and bringing new products to market. Prior, Ms. Klugewicz spent over twenty years at Pall Corporation, where she served as Sr. Vice President of Global Scientific & Laboratory Services, responsible for the efficient and profitable service delivery of the company’s products and solutions, and as SVP of Global Quality Assurance & Regulatory Compliance of the Life Sciences division, leading regulatory and quality assurance activities across multiple manufacturing sites to support operational efficiency and compliance.

Ms. Klugewicz received a Bachelor of Science degree in Neurobiology from Stony Brook University and obtained a Master of Science in Biochemistry from Adelphi University. She has been a featured speaker at various industry events and is involved in various committees, including the Women in Science & Engineering Committee at Stony Brook University.

Ms. Klugewicz commented, “I am very excited at the opportunity to join Misonix and to be part of a fast-growing company that is leveraging its unique proprietary ultrasonic technology to bring to market medical devices that deliver demonstrated clinical benefits and improve patient outcomes. I look forward to utilizing my range of skills, knowledge and experiences gained across the industry to promote innovation, improved productivity, team building and organizational success, while supporting Misonix’s business goals. I look forward to working with the Board and the Misonix team to lead the company to its next phase of growth and success.”

About Misonix, Inc.

Misonix, Inc. (NASDAQ: MSON) designs, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix’s proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company’s web site at www.misonix.com.

Contact: 
Joe DwyerJoseph Jaffoni, Norberto Aja, Jennifer Neuman
Chief Financial OfficerJCIR
Misonix, Inc.212-835-8500 or mson@jcir.com 
631-927-9113

SOURCE: GlobeNewswire March 4, 2019

Renowned orthopaedic surgeon, Michael Alexiades, MD, appointed as newest member of Intellijoint Surgical’s Scientific Advisory Board

Renowned orthopaedic surgeon, Michael Alexiades, MD, appointed as newest member of Intellijoint Surgical’s Scientific Advisory Board

WATERLOO, ON, Feb. 21, 2019 /PRNewswire/ – Intellijoint Surgical®, a Canadian-held company developing and commercializing smart navigation for total joint replacements, is pleased to announce the appointment of Michael Alexiades, MD, to its Scientific Advisory Board (SAB). Dr. Alexiades is an orthopaedic surgeon at Hospital for Special Surgery (HSS) in New York City – the number one American hospital for orthopedics nine years in a row ranked by the US News & World Report. Dr. Alexiades will play an active role in clinical research and surgeon education while guiding the development of an expanded product portfolio bringing Intellijoint Surgical’s core technology to more surgical applications.

“Intellijoint Surgical is a true innovator in orthopaedic navigation,” commented Dr. Alexiades following his appointment. “As a high volume orthopedic surgeon, their flagship product – Intellijoint HIP® – enhances my accuracy during total hip arthroplasty (THA). It doesn’t slow me down and it is cost-effective for our hospital. I am excited to join the advisory team to further develop this technology and prove the benefits it has for patients.”

Dr. Alexiades specializes in hip, knee, shoulder and elbow surgery including arthroscopic surgery, joint-sparing surgery and total joint replacement. He is a trailblazer in the mini-anterior approach to THA and an early adopter of the partial knee replacement. Dr. Alexiades has been in practice for 29 years, all of which have been at HSS. In the last two years, Dr. Alexiades has completed hundreds of THAs using Intellijoint HIP to deliver the best possible outcomes for his patients.

“Dr. Alexiades was an essential team member in the development of Intellijoint HIP for the anterior approach,” explained Armen Bakirtzian, CEO & co-founder of Intellijoint Surgical. “His experience, knowledge and keen interest in developing technology to improve total joint replacement outcomes is an invaluable asset and I am so happy he is expanding his role by joining our SAB.”

Outside his clinical work, Dr. Alexiades is active in New York’s Finest Foundation, chairs the NYPD Article II Medical Board and is Chief Surgeon for the NY State Troopers Association. He is passionate about the education and training of residents and fellows, and is an examiner for the American Board of Orthopedic Surgery, with responsibility for the education and certification of orthopedic surgeons.

Dr. Alexiades joins an esteemed group of orthopaedic surgeons on Intellijoint Surgical’s SAB: Chairman, Dr. Allan Gross at Mount Sinai Hospital (Toronto, Ont.), and members: Dr. Wayne Paprosky at Rush University Medical Center (Chicago, Ill.); Dr. Michael Bradley at South County Hospital (South Kingstown, R.I.); and Dr. Ran Schwarzkopf at NYU Langone’s Hospital for Joint Diseases (New York, N.Y.).

About Intellijoint Surgical:

Intellijoint Surgical® develops and commercializes surgical navigation solutions. Intellijoint’s flagship product, Intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure proper size selection and positioning of orthopaedic implants during total hip replacements. Intellijoint is committed to improving patients’ lives by providing every surgeon with effective, easy-to-use technology.

Intellijoint Surgical is the recipient of the North American Frost & Sullivan Enabling Technology Leadership Award, the Futurpreneur Shopify True Grit Award and the Growing Strong Futurpreneur Award.

SOURCE Intellijoint Surgical Inc., PRNewswire, Feb 21, 2019

Related Links

https://www.intellijointsurgical.com/
Generation Z drops out of the recruitment process

Generation Z drops out of the recruitment process

Almost one-in-five of Generation Z applicants are dropping out of the recruitment process, even after being offered a job

According to a new report developed by Oleeo, the leading provider of e-Recruitment software, in collaboration with MyKindaFuture, 18 per cent of Generation Z applicants are dropping out of the recruitment process.

Born in 1996 or later, Generation Z are predicted to outnumber the Millennial generation globally by as early as 2019. Whilst Millennials currently make up 40% of the UK workforce, Generation Z are now leaving education to begin their careers and will quickly take over the Millennial workforce population.

Lack of correct engagement has been highlighted as the driving force behind why so many are leaving the process.

Statements from the Oleeo article, include those of:

Charles Hipps, CEO and Founder, of Oleeo said: “Gen Z demand a different kind of relationship with organisations. In a digital and relationship-centric era they expect to build a personal connection with potential employers in order to decide where to apply, and which offers to accept. With this generation used to using up to six screens at any one time, these relationships need to be developed across multiple platforms. Added to this, Gen Z expect information to be hyper relevant to them. For employers recruiting large numbers of young people, that’s an incredible mix of demands to meet, which is why technology is so important”.

William Akerman, Founder & Managing Director of social enterprise MyKindaFuture, which helps connect employers and young people, agrees: “Technology has the ability to streamline the recruitment process for recruiters, whilst increasing engagement for applicants.  It’s a win, win.”

MyKindaFuture has worked with the likes of Skanska, Rolls Royce and Civil Service Fast Stream and Early Talent.  “We’re seeing technologies like video interviews, e-tray exercises, and digi-mentoring being used to engage with young people, improve the applicant’s experience and reduce drop-out rates,” continued Akerman.

Vanessa Soames, Graduate Recruitment Director at Police Now, a company featured in the report, commented: “In an on-demand society, poor processes and communication in the recruitment process can’t be hidden from candidates. If a candidate has an unpleasant experience, it is likely this will be shared online and the experience of one person is brand-damaging for organisations.”

Charles Hipps concludes: “Organisations trying to recruit Generation Z talent have a lot to think about. They have to be adept at reaching out to young people in schools, in universities, while they’re completing apprenticeships or even taking a gap year. They cannot rely on the same old routes and approaches. At the same time, they must give candidates a great recruitment experience from the outset, and at every step of the way, until the young person is onboard and working.  That means engaging with large numbers of very different young people, but every time in a meaningful way.  With HR teams already under considerable resource pressure, technology is inevitably going to be a vital enabler in early years recruiting.”

SOURCE: The Recruiting Times, Dec 17, 2018